59 related articles for article (PubMed ID: 11410494)
1. Patient-derived scaffolds representing breast cancer microenvironments influence chemotherapy responses in adapted cancer cells consistent with clinical features.
Leiva MC; Gustafsson A; Garre E; Ståhlberg A; Kovács A; Helou K; Landberg G
J Transl Med; 2023 Dec; 21(1):924. PubMed ID: 38124067
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?
Shimoni A; Körbling M
Crit Rev Oncol Hematol; 2002 Feb; 41(2):241-50. PubMed ID: 11856599
[TBL] [Abstract][Full Text] [Related]
3. Treating Metastatic Brain Cancers With Stem Cells.
Sadanandan N; Shear A; Brooks B; Saft M; Cabantan DAG; Kingsbury C; Zhang H; Anthony S; Wang ZJ; Salazar FE; Lezama Toledo AR; Rivera Monroy G; Vega Gonzales-Portillo J; Moscatello A; Lee JY; Borlongan CV
Front Mol Neurosci; 2021; 14():749716. PubMed ID: 34899179
[TBL] [Abstract][Full Text] [Related]
4. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
[TBL] [Abstract][Full Text] [Related]
5. Versatile exclusion-based sample preparation platform for integrated rare cell isolation and analyte extraction.
Pezzi HM; Guckenberger DJ; Schehr JL; Rothbauer J; Stahlfeld C; Singh A; Horn S; Schultz ZD; Bade RM; Sperger JM; Berry SM; Lang JM; Beebe DJ
Lab Chip; 2018 Nov; 18(22):3446-3458. PubMed ID: 30334061
[TBL] [Abstract][Full Text] [Related]
6. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
7. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
Schwarzenbach H; Pantel K; Kemper B; Beeger C; Otterbach F; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(5):R71. PubMed ID: 19772563
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells as markers for cancer risk assessment and treatment monitoring.
Kasimir-Bauer S
Mol Diagn Ther; 2009; 13(4):209-15. PubMed ID: 19712001
[TBL] [Abstract][Full Text] [Related]
10. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
[TBL] [Abstract][Full Text] [Related]
11. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
Aktas B; Tewes M; Fehm T; Hauch S; Kimmig R; Kasimir-Bauer S
Breast Cancer Res; 2009; 11(4):R46. PubMed ID: 19589136
[TBL] [Abstract][Full Text] [Related]
12. ProtEx technology for the generation of novel therapeutic cancer vaccines.
Schabowsky RH; Sharma RK; Madireddi S; Srivastava A; Yolcu ES; Shirwan H
Exp Mol Pathol; 2009 Jun; 86(3):198-207. PubMed ID: 19454266
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.
Buter J; Pinedo HM
Curr Oncol Rep; 2003 May; 5(3):171-6. PubMed ID: 12667414
[No Abstract] [Full Text] [Related]
14. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
[TBL] [Abstract][Full Text] [Related]
15. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
18. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
